Table 4.
Resistance prevalence for selected drug-bug pairs by patient type, U.S. 1999–2002
| unit: % | ||||
| Pair | Bacterium (resistant to) → drug | ICU patients | non-ICU inpatients | Outpatients |
| A | PAE → Ciprofloxacin/ofloxacin | 32 | 25 | 23 |
| B | PAE → Levofloxacin | 37 | 28 | 25 |
| C | PAE → Imipenem | 18 | 12 | 9 |
| D | PAE → Ceftazidime | 13 | 8 | 5 |
| E | PAE → Piperacillin | 16 | 11 | 6 |
| F | SAU → Methicillin | 47 | 38 | 23 |
| G | Enterococcus spp → Vancomycin | 13 | 11 | 4 |
| H | ECO → Cef3* | 1 | 1 | 0 |
| I | ECO → Quinolone** | 5 | 4 | 2 |
| J | KPN → Cef3 | 6 | 5 | 2 |
| K | Enterobacter spp → Cef3 | 26 | 21 | 10 |
| L | Enterobacter spp → Carbapenum | 1 | 1 | 1 |
| M | CNS → Methicillin | 75 | 63 | 46 |
| N | Pneumococcus → Penicillin | 18 | 17 | 17 |
| O | Pneumococcus → Cef3 | 7 | 8 | 6 |
| Mean | 21 | 17 | 12 | |
*Cef3 (3rd generation cephalosporin) = ceftazidime, cefotaxime or ceftriaxone;
**Quinolone = ciprofloxacin, ofloxacin or levofloxacin.